Cardiovascular Agents

• 

  Subject Areas on Research

  • 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
  • 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. 
  • A health literacy pilot intervention to improve medication adherence using Meducation® technology. 
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 
  • ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 
  • Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute ischemic syndromes. 
  • Adenosine for myocardial protection in acute myocardial infarction. 
  • Adenosine-induced transient asystole for intracranial aneurysm surgery: a retrospective review. 
  • Adverse drug events in high risk older outpatients. 
  • Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time. 
  • American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. 
  • Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. 
  • Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. 
  • BNP-guided heart failure therapy in older patients. 
  • Back to the future: improving the use of guidelines-recommended coronary disease secondary prevention at the dawn of the precision medicine era. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Calcineurin signaling in human cardiac hypertrophy. 
  • Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. 
  • Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications. 
  • Cardiovascular Medications and Fractures: Dodging Complexity. 
  • Cardiovascular drug development: is it dead or just hibernating? 
  • Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. 
  • Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). 
  • Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study. 
  • Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study. 
  • Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. 
  • Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. 
  • Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. 
  • Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus. 
  • Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. 
  • Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. 
  • Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). 
  • Complement activation and cardiac surgery: A novel target for improving outcomes 
  • Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. 
  • Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. 
  • Contemporary therapy of acute ST-elevation myocardial infarction. 
  • Cost of ventricular assist devices: can we afford the progress? 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. 
  • Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. 
  • Decongestion in acute heart failure. 
  • Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies. 
  • Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience. 
  • Developing New Treatments for Heart Failure: Focus on the Heart. 
  • Disease management of congestive heart failure. 
  • Does ranolazine have a place in the treatment of acute coronary syndromes? 
  • Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome. 
  • Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? 
  • Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. 
  • Drug-induced lung injury. 
  • Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). 
  • Economic end points in phase II trials. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis. 
  • Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. 
  • Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. 
  • Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. 
  • Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. 
  • Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod. 
  • Enabling social listening for cardiac safety monitoring: Proceedings from a drug information association-cardiac safety research consortium cosponsored think tank. 
  • Enhancement of cardiac function by cyclocreatine in models of cardiopulmonary bypass. 
  • Enhancement of the force-frequency effect on myocardial contractility by adrenergic stimulation in conscious dogs. 
  • Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. 
  • Evidence-based therapy prescription in high-cardiovascular risk patients: the REACT study. 
  • Evolution of amino-terminal pro-B type natriuretic peptide testing in heart failure. 
  • Extended-release ranolazine: critical evaluation of its use in stable angina. 
  • Few Disparities in Baseline Laboratory Testing After the Diuretic or Digoxin Initiation by Medicare Fee-For-Service Beneficiaries. 
  • Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. 
  • From acute decompensated to chronic heart failure. 
  • Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. 
  • Gender-related differences in acute aortic dissection. 
  • Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. 
  • Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. 
  • Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals: Findings From Get With The Guidelines-Heart Failure. 
  • Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • High-resolution CT of drug-induced lung disease. 
  • Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. 
  • Identifying targets for cardiovascular medication adherence interventions through latent class analysis. 
  • Impact of a depression care management program for hospitalized cardiac patients. 
  • Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. 
  • Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. 
  • Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. 
  • Indications for pacing in the treatment of bradyarrhythmias. Report of an independent study group. 
  • Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. 
  • Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 
  • International variation in the use of evidence-based medicines for acute coronary syndromes. 
  • Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Intramyocardial, autologous CD34+ cell therapy for refractory angina. 
  • Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. 
  • Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction. 
  • Issues with care in the elderly patient presenting with acute ischemia. 
  • Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Lessons learned from clinical trials in acute heart failure: phase 3 drug trials. 
  • Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. 
  • Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. 
  • Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. 
  • Lower extremity amputation in peripheral artery disease: improving patient outcomes. 
  • Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. 
  • Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study. 
  • Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery ® and the American Venous Forum. 
  • Medical and surgical management of coronary artery disease in women. 
  • Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. 
  • Medication adherence: a call for action. 
  • Medication non-adherence after myocardial infarction: an exploration of modifying factors. 
  • Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. 
  • Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. 
  • Metaanalysis and review of heart failure disease management randomized controlled clinical trials. 
  • Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. 
  • NO/redox disequilibrium in the failing heart and cardiovascular system. 
  • Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. 
  • New precompetitive paradigms: focus on cardiac safety. 
  • Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. 
  • Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. 
  • Outpatient management of heart failure in the United States, 2006-2008. 
  • Paroxysmal high-grade atrioventricular block and syncope in a previously healthy child: what is the mechanism? 
  • Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. 
  • Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). 
  • Patient-centered cardiac care for the elderly: TIME for reflection. 
  • Patterns and outcomes of drug-eluting coronary stent use in clinical practice. 
  • Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. 
  • Pediatric cardiovascular drug trials, lessons learned. 
  • Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry. 
  • Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. 
  • Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. 
  • Pharmacogenetics in heart failure trials. 
  • Pharmacological and emerging therapies in the treatment of chronic angina. 
  • Pharmacological properties of tropyl benzilate hydrochloride (BAT) and its N-allyl derivative (NTB). 
  • Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. 
  • PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. 
  • Predictors of contemporary coronary artery bypass grafting outcomes. 
  • Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. 
  • Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. 
  • Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. 
  • Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. 
  • Provisional stenting versus routine stenting: is it worth the price? 
  • Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants. 
  • Pulmonary drug toxicity: radiologic and pathologic manifestations. 
  • Putting the Acute Coronary Syndrome in Context After 80 Years of Age. 
  • Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). 
  • Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. 
  • Quantifying the utility of taking pills for cardiovascular prevention. 
  • Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey. 
  • Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). 
  • Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. 
  • Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). 
  • Rational use of medications: if Canada can't do it ... 
  • Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. 
  • Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. 
  • Renal function, concomitant medication use and outcomes following acute coronary syndromes. 
  • Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. 
  • Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. 
  • Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients. 
  • Sample size and interim analysis issues for dose selection. 
  • Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. 
  • Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 
  • Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. 
  • Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. 
  • Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. 
  • Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). 
  • Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Surgical correction of aortic valve insufficiency after left ventricular assist device implantation. 
  • Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. 
  • Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. 
  • Synergistic effects of exposure to concentrated ambient fine pollution particles and nitrogen dioxide in humans. 
  • Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. 
  • Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. 
  • The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. 
  • The Cardiac Safety Research Consortium enters its second decade: An invitation to participate. 
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development. 
  • The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. 
  • The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. 
  • The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. 
  • The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study. 
  • The disconnect between phase II and phase III trials of drugs for heart failure. 
  • The effect of a disease management algorithm and dedicated postacute coronary syndrome clinic on achievement of guideline compliance: results from the parkland acute coronary event treatment study. 
  • The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. 
  • The immediate impact of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial on the management of stable angina. 
  • The impact of medication use in a multicomponent intervention: results from the WISEWOMAN program. 
  • The meanings associated with medicines in heart failure patients. 
  • The neurohormonal network in the RAAS can bend before breaking. 
  • The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists. 
  • The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. 
  • The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. 
  • The use of vasoactive agents via peripheral intravenous access during transport of critically III infants and children. 
  • The year in cardiovascular surgery. 
  • Therapy insight: how changes in renal function with increasing age affect cardiovascular drug prescribing. 
  • Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. 
  • Translation of acute coronary syndrome therapies: from evidence to routine clinical practice. 
  • Treatment of non-ST-elevation acute coronary syndrome in the elderly: current practice and future opportunities. 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database. 
  • Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. 
  • Update on perioperative care of the cardiac patient for noncardiac surgery. 
  • Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. 
  • Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. 
  • Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. 
  • Use of guideline-recommended therapies for heart failure in the Medicare population. 
  • Using measures of disease progression to determine therapeutic effect: a sirens' song. 
  • Whatever happened to the polypill? 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Warner, David Samuel, Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology